These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cancer research. Taking garbage in, tossing cancer out? Garber K Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952 [No Abstract] [Full Text] [Related]
3. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma]. Tobinai K Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092 [No Abstract] [Full Text] [Related]
4. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug. Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821 [No Abstract] [Full Text] [Related]
6. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks. Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098 [TBL] [Abstract][Full Text] [Related]
7. Current status of bortezomib in the treatment of multiple myeloma. Cavo M Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361 [TBL] [Abstract][Full Text] [Related]
8. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Tong Y; Qian J; Li Y; Meng H; Jin J Am J Hematol; 2007 May; 82(5):403-4. PubMed ID: 17133426 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease. Terpos E Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229 [No Abstract] [Full Text] [Related]
11. Enhancing care and managing side effects in patients receiving bortezomib. Colson K Clin Adv Hematol Oncol; 2006 May; 4(5):6-7; discussion 8; suppl 13. PubMed ID: 16832860 [No Abstract] [Full Text] [Related]
12. Bortezomib for myeloma -- much ado about something. Dispenzieri A N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811 [No Abstract] [Full Text] [Related]
15. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib. Yokose N; Hirakawa T; Inokuchi K Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724 [No Abstract] [Full Text] [Related]
16. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma]. Rukavitsyn OA Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936 [No Abstract] [Full Text] [Related]
17. Subcutaneous bortezomib: a step towards optimised drug use. Mateos MV Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716 [No Abstract] [Full Text] [Related]
18. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Rosiñol L; Montoto S; Cibeira MT; Bladé J Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib induced a phrenic palsy in a multiple myeloma patient. Nizeica V; Collet P; Marotte H Ann Hematol; 2013 Aug; 92(8):1135-6. PubMed ID: 23370597 [No Abstract] [Full Text] [Related]
20. Bortezomib-induced acute congestive heart failure: a case report and review of literature. Subedi A; Sharma LR; Shah BK Ann Hematol; 2014 Oct; 93(10):1797-9. PubMed ID: 24599584 [No Abstract] [Full Text] [Related] [Next] [New Search]